Latest News

Nvidia's leadership is in question, but demand for Broadcom’s custom AI chips and Micron's memory isn't. Both stocks trade at low multiples of forward earnings.

Recent developments may have changed the company's outlook.

National Vision (NASDAQ:EYE) reported higher third-quarter revenue and more than doubled its adjusted earnings per share as customers spent more on eyewear, offsetting a decline in traffic. The company also accelerated its store-opening plans for 2027, even as it revised its 2026 revenue outlook to

EZCORP (NASDAQ:EZPW) reported record annual revenue and pawn loans outstanding for fiscal 2026, as growth in lending and merchandise sales helped drive a 33% increase in fourth-quarter adjusted EBITDA. Chief Executive Officer Lachie Given said the company’s core pawn business, rather than gold scra

Astera Labs (NASDAQ:ALAB) sees an opportunity to grow faster than underlying demand for AI infrastructure as it expands its product lineup and increases the value of its chips in each computing system, Senior Vice President of Finance Nick Aberle said at a BMO event. Aberle said the company could c

Altimmune (NASDAQ:ALT) is ramping up a late-stage trial of its experimental drug pemvidutide for a serious liver disease and preparing for a December meeting with the U.S. Food and Drug Administration on a potential phase III program in alcohol use disorder. On its third-quarter earnings call Nov.

Alvotech (NASDAQ:ALVO) expects its full-year revenue and adjusted earnings to land near the lower end of its guidance range, as the biosimilar maker works to increase deliveries following a manufacturing slowdown. Executives said on the company’s third-quarter earnings call that they expect the fin

Absci (NASDAQ:ABSI) expects to release interim data from its experimental pattern hair loss treatment in December, followed by a fuller assessment in early 2027, executives said during the company’s third-quarter business update on November 12. The company is also preparing a mid-2027 start for a P

Merck KGaA (ETR:MRK) raised its full-year 2026 outlook for the third time after faster third-quarter sales growth in its Life Science and Electronics businesses offset pressure on its Healthcare portfolio. The company now expects group net sales of EUR 21.5 billion to EUR 21.9 billion, up from its

Allot (NASDAQ:ALLT) reported third-quarter revenue growth of 16% and raised the midpoint of its full-year revenue outlook, as its security-as-a-service business expanded and existing customers placed orders for its SMART products. Revenue rose to $30.6 million in the quarter, the company’s fifth co

Endeavour Mining (LON:EDV) expects to produce gold in the lower half of its full-year guidance range after suspending underground mining at its Mana operation, even as higher gold prices helped drive record cash flow in the first nine months of 2026. Chief Executive Officer Ian Cockerill said the c

After CEO Jensen Huang resigned, the chipmaker's shares traded about 35% below their October record shortly after the Nov. 12 open. Are they finally cheap enough?

These five dividend payers sell things people don't stop buying, and the market is pricing them accordingly.

Nvidia just lost its CEO -- so why is Micron stock down?

Record freight rates lifted profit, and most of Q4 is already booked.

Margins climbed while customer traffic softened at the eyewear chain.

Medicare payments now flowing for its esophageal test, with record October volume.

The semiconductor specialist is searching for a new CEO.

CoreWeave's Q3 revenue grew nearly 170% and backlog topped $130 billion, easing debt concerns as analysts reaffirmed ratings despite lowering some price targets.

The Vanguard S&P 500 ETF offers a way to invest in the next bear market without betting on any single sector.

Starlink Mobile will face some hurdles, but it has a few things working in its favor, too.

If bears are prowling next year, these ETFs can help investors thrive.

Peyto Exploration and Development is growing its dividend as natural gas fundamentals continue to improve.

Yorvipath sales doubled as Ascendis eyes a new therapy area

History indicates this is a great time to invest in stocks.